On April 30, 2020, Sanofi received a positive opinion from the European Medicines Agency (EMA)’s Committee for Medical Products for Human Use (CHMP), recommending the granting of marketing authorization for its biosimilar of insulin aspart (NovoRapid, marketed by Novo Nordisk).  Insulin aspart is a fast-acting insulin analogue that is absorbed rapidly by the body and is indicated for the treatment of diabetes mellitus in adults, adolescents and children.